UCB and Veeva collaborate to advance the patient experience in clinical trials
Brussels (Belgium), and Pleasanton, CA (US), 23 May 2023 (07:00 CET) - UCB, a global biopharmaceutical company, and Veeva Systems (NYSE: VEEV), today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial efficiency. The collaboration will see UCB adopt Veeva ePRO and Veeva eConsent to provide a patient centric digital experience to study participants and will actively influence the strategic direction of these and other applications based on learnings. Together, Veeva and UCB aim to set a new industry standard for digital clinical trials with multiple applications that meet the unique needs of patients.
“The partnership between UCB and Veeva presents a significant opportunity to drive progress in clinical study execution,” said Iris Loew-Friedrich, executive vice president and chief medical officer at UCB. “By delivering digital clinical trial, we reduce the burden on study participants and sites, improve trial accessibility to ensure we put patients at the heart of everything we do.”
Veeva ePRO simplifies the design, management, and completion of electronic patient reported outcomes (ePRO), with seamless data flow among sponsors, sites, and patients. Veeva eConsent simplifies the set-up, completion, and review of consent for patients, sites, and study teams. Both applications are available to patients through MyVeeva for Patients, which provides one point of access for all their clinical trial actions, scheduling, and communications. Veeva ePRO and Veeva eConsent are part of Veeva Vault Clinical Suite, a set of integrated capabilities that simplify the technology landscape of clinical trials for both clinical operations and clinical data management.
“We’re excited to partner with UCB to advance patient-centric digital trials,” said Veeva CEO Peter Gassner. “Their input will help advance Veeva’s approach to solutions that make digital trials work even better for sponsors, sites, and patients.”
Edwin Erckens, chief digital technology officer at UCB stated: “UCB’s collaboration with Veeva is yet another proof point of our ongoing effort to drive digital business transformation. By leveraging our collective expertise, we can push the boundaries of what technology can achieve to improve the clinical trial process.”
Financial details of the collaboration were not disclosed.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,600 people in approximately 40 countries, the company generated revenue of €5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
For further information
Scott Fleming, R&D Communications (UCB), +447702777378, firstname.lastname@example.org
Antje Witte Investor Relations (UCB), +32.2.559.94.14, email@example.com
Laurent Schots, Corporate Communications (UCB), +32.2.559.92.64, firstname.lastname@example.org
Jeremy Whittaker, Veeva Systems, +49-695-095-5486, email@example.com
Forward looking statements
This press release may contain forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.
Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.
UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
Stay up-to-date on the latest news and information from UCB